SG11201407613RA - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents

Process for making hydroxylated cyclopentylpyrimidine compounds

Info

Publication number
SG11201407613RA
SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA
Authority
SG
Singapore
Prior art keywords
international
boulder
colorado
array biopharma
walnut street
Prior art date
Application number
SG11201407613RA
Other languages
English (en)
Inventor
Jonathan W Lane
Travis Remarchuk
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of SG11201407613RA publication Critical patent/SG11201407613RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201407613RA 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds SG11201407613RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Publications (1)

Publication Number Publication Date
SG11201407613RA true SG11201407613RA (en) 2015-01-29

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407613RA SG11201407613RA (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Country Status (19)

Country Link
US (1) US9309204B2 (fr)
EP (1) EP2861583B1 (fr)
JP (1) JP6214636B2 (fr)
KR (1) KR20150020211A (fr)
CN (1) CN104487430B (fr)
AU (1) AU2013262568B2 (fr)
BR (1) BR112014028570A2 (fr)
CA (1) CA2873653A1 (fr)
DK (1) DK2861583T3 (fr)
ES (1) ES2588878T3 (fr)
HK (1) HK1208673A1 (fr)
IL (1) IL235714A0 (fr)
MA (1) MA37649B1 (fr)
MX (1) MX2014013865A (fr)
PL (1) PL2861583T3 (fr)
RU (1) RU2014151017A (fr)
SG (1) SG11201407613RA (fr)
SI (1) SI2861583T1 (fr)
WO (1) WO2013173736A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407591PA (en) 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028589B1 (pt) 2012-05-17 2022-08-23 Genentech, Inc. Ciclopentilpirimidina hidroxilada, seu processo de fabricação e seus intermediários
AU2013262548B2 (en) 2012-05-17 2017-09-21 Genentech, Inc. Amorphous form of an AKT inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
SI2850054T1 (en) 2012-05-17 2018-06-29 Genentech, Inc. A process for the production of amino acid compounds
JP6374503B2 (ja) 2013-11-15 2018-08-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリミジニルシクロペンタン化合物の調製方法
RU2697707C9 (ru) * 2013-11-27 2019-10-03 Саншайн Лейк Фарма Ко., Лтд. Процессы приготовления производных соединений дигидропиримидина и их промежуточных продуктов
US10457648B2 (en) * 2014-09-26 2019-10-29 Genentech Inc. Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
WO2021254920A1 (fr) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Procédé de fabrication de composés de cyclopentylpyrimidine hydroxylée
KR20230035773A (ko) * 2021-09-06 2023-03-14 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134212C (zh) 1993-12-12 2004-01-14 阿格罗吉恩有限公司 保护植物免受真菌侵染的新方法
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (fr) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
BRPI0813993A2 (pt) 2007-07-05 2015-06-16 Array Biopharma Inc Ciclopentanos de pirimidila como inibidores de proteína quinase akt
WO2009047255A1 (fr) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
BRPI0906798A2 (pt) 2008-01-09 2015-07-14 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados como inibidores de proteína quinase akt
JP5551707B2 (ja) * 2008-10-15 2014-07-16 アムジエン・インコーポレーテツド スピロ環gpr40調節因子
CA2758484A1 (fr) 2009-04-15 2010-10-21 David A. Degoey Composes antiviraux
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
SI2850054T1 (en) 2012-05-17 2018-06-29 Genentech, Inc. A process for the production of amino acid compounds
BR112014028589B1 (pt) 2012-05-17 2022-08-23 Genentech, Inc. Ciclopentilpirimidina hidroxilada, seu processo de fabricação e seus intermediários
SG11201407591PA (en) 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
WO2014071194A2 (fr) 2012-11-01 2014-05-08 Katz Robert S Méthodes de traitement de la fibromyalgie
CA2901577A1 (fr) 2013-02-18 2014-08-21 The Scripps Research Institute Modulateurs des recepteurs de la vasopressine a pouvoir therapeutique
WO2014150395A1 (fr) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Composés anti-pcsk9 et méthodes de traitement et/ou de prévention de maladies cardio-vasculaires

Also Published As

Publication number Publication date
JP2015518837A (ja) 2015-07-06
PL2861583T3 (pl) 2016-12-30
US20150099881A1 (en) 2015-04-09
SI2861583T1 (sl) 2016-10-28
KR20150020211A (ko) 2015-02-25
IL235714A0 (en) 2015-02-01
EP2861583B1 (fr) 2016-06-29
EP2861583A1 (fr) 2015-04-22
AU2013262568A1 (en) 2015-01-22
RU2014151017A (ru) 2016-07-10
MA37649B1 (fr) 2017-03-31
CN104487430A (zh) 2015-04-01
MX2014013865A (es) 2015-05-07
DK2861583T3 (en) 2016-10-03
WO2013173736A1 (fr) 2013-11-21
HK1208673A1 (en) 2016-03-11
CN104487430B (zh) 2016-08-24
AU2013262568B2 (en) 2017-08-31
BR112014028570A2 (pt) 2018-04-24
MA37649A1 (fr) 2016-06-30
JP6214636B2 (ja) 2017-10-18
ES2588878T3 (es) 2016-11-07
CA2873653A1 (fr) 2013-11-21
US9309204B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
SG11201407613RA (en) Process for making hydroxylated cyclopentylpyrimidine compounds
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201807834WA (en) Bridged bicyclic inhibitors of menin-mll and methods of use
SG11201909278SA (en) Fungicidal oxadiazoles
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201408067YA (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
SG11201804934PA (en) Novel Compounds
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201407458XA (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201408271VA (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201403402VA (en) Compounds
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production